Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Invasive urothelial carcinoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    78 result(s) found for: Invasive urothelial carcinoma. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2022-000514-33 Sponsor Protocol Number: OZBS62.20366 Start Date*: 2022-10-10
    Sponsor Name:Erasmus MC
    Full Title: CHemotherapy And Sequential ImmunoTherapy for locally advanced urothelial cancer: the CHASIT study
    Medical condition: Urothelial cancer of the bladder, upper urinary tract or urethra.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    20.0 100000004864 10046723 Urothelial carcinoma ureter LLT
    20.0 100000004864 10046728 Urothelial carcinoma urethra LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004876-16 Sponsor Protocol Number: SURE-02 Start Date*: 2021-11-10
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: SURE-02_An open label, single-arm, phase 2 study of perioperative pembrolizumab plus sacituzumab govitecan for patients with muscle-invasive bladder cancer who cannot receive or refuse cisplatin-ba...
    Medical condition: muscle-invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002244-23 Sponsor Protocol Number: INCB24360-901 Start Date*: 2021-07-28
    Sponsor Name:Incyte Corporation
    Full Title: An Open-Label, Randomized, Phase 2, Umbrella Study of Various Neoadjuvant Therapies for Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Cisplatin-Ineligible or Refuse ...
    Medical condition: Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Cisplatin-Ineligible or Refuse Cisplatin Therapy and Undergoing Radical Cystectomy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003565-10 Sponsor Protocol Number: SAKK06/17 Start Date*: 2018-12-03
    Sponsor Name:Swiss Group for Clinical Cancer Research
    Full Title: Neoadjuvant and adjuvant durvalumab in combination with neoadjuvant chemotherapy in patients with operable urothelial cancer. A multicenter, single-arm phase II Trial.
    Medical condition: muscle invasive urothelial cancer (MIUC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003625-17 Sponsor Protocol Number: CA209-275 Start Date*: 2015-01-27
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A phase II single arm clinical trial of nivolumab (BMS-936558) in subjects with metastatic or unresectable urothelial cancer who have progressed or recurred following treatment with a platinum agen...
    Medical condition: metastatic or unresectable urothelial cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046723 Urothelial carcinoma ureter LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046714 Urothelial carcinoma bladder LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064467 Urothelial carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046728 Urothelial carcinoma urethra LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) BE (Completed) SE (Completed) CZ (Completed) FI (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003626-40 Sponsor Protocol Number: CA209-274 Start Date*: 2016-07-13
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma
    Medical condition: Subjects with High Risk Invasive Urothelial Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) SE (Trial now transitioned) PL (Trial now transitioned) IE (Trial now transitioned) GB (GB - no longer in EU/EEA) GR (Trial now transitioned) RO (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000658-37 Sponsor Protocol Number: CHT3 Start Date*: 2016-08-02
    Sponsor Name:Medizinische Universität Wien
    Full Title: Neoadjuvant chemotherapy with gemcitabine and cisplatin (GC) versus dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) in muscle-invasive urothelial carcinoma of the bladder
    Medical condition: Urothelial carcinoma of the urinary bladder
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022653-41 Sponsor Protocol Number: INT52/10 Start Date*: 2010-11-25
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Phase II study of neoadjuvant cisplatin and gemcitabine plus sorafenib for patients with transitional cell carcinoma of the bladder.
    Medical condition: Muscle-invasive transitional cell carcinoma of the bladder at clinical stage T>/=2N0.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005084 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002009-40 Sponsor Protocol Number: MK-3475-045 Start Date*: 2014-09-01
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel, Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer
    Medical condition: Metastatic or locally advanced/unresectable urothelial cancer that has recurred or progressed following platinum-based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IE (Completed) IT (Completed) DE (Completed) ES (Completed) HU (Completed) AT (Completed) NL (Completed) SE (Completed) DK (Completed) GB (Completed) PT (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-001167-23 Sponsor Protocol Number: IMMU-132-06 Start Date*: 2019-03-20
    Sponsor Name:Immunomedics, Inc.
    Full Title: A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy
    Medical condition: Histologically documented locally advanced (tumor [T] 4b, any node [N]; or any T, N 2-3) or metastatic (M1, Stage IV) urothelial or non-urothelial carcinoma of the urinary tract predominant
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10077840 Urothelial cancer of renal pelvis LLT
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    20.0 100000004864 10046723 Urothelial carcinoma ureter LLT
    20.0 100000004864 10046728 Urothelial carcinoma urethra LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) GR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004017-27 Sponsor Protocol Number: EUOG-2016-003 Start Date*: 2019-05-08
    Sponsor Name:European Uro-Oncology Group (EUOG)
    Full Title: "Neo-adjUvant veRsus AdjuvaNt chemotherapy in Upper Tract Urothelial Carcinoma: A feaSibility phase II randomized clinical trial (“URANUS”)
    Medical condition: Patients with upper urinary tract transitional cell carcinoma (UTUC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NO (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005565-13 Sponsor Protocol Number: 17000139BLC2002 Start Date*: 2021-10-26
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are...
    Medical condition: Muscle-Invasive Urothelial Carcinoma of the Bladder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    21.0 100000004864 10046720 Urothelial carcinoma bladder stage II LLT
    21.0 100000004864 10046721 Urothelial carcinoma bladder stage III LLT
    21.0 100000004864 10046722 Urothelial carcinoma bladder stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-000294-67 Sponsor Protocol Number: CA209-6L6 Start Date*: 2022-12-21
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase II Study of Adjuvant Nivolumab Switch from Intravenous (IV) to Subcutaneous (SC) Use in Participants with Resected Stage III or Stage IV Melanoma or High Risk Invasive Urothelial Carcinoma ...
    Medical condition: Stage III A/B/C/D, Stage IV melanoma or Muscle-Invasive Urothelial Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005603-25 Sponsor Protocol Number: WO29636 Start Date*: 2015-07-30
    Sponsor Name:Roche Farma, S.A., que representa en España a F. Hoffmann-La Roche Ltd.
    Full Title: A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) VERSUS OBSERVATION AS ADJUVANT THERAPY IN PATIENTS WITH PD-L1-SELECTED, HIGH RISK MUSCLE INVASIVE BLADDER C...
    Medical condition: Muscle-invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10022877 Invasive bladder cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FI (Completed) CZ (Completed) DE (Completed) BE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) FR (Completed) GR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-003248-63 Sponsor Protocol Number: QBGJ398-302 Start Date*: 2020-02-19
    Sponsor Name:QED Therapeutics, Inc.
    Full Title: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alt...
    Medical condition: Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10046731 Urothelial carcinoma urethra recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Completed) FR (Completed) BE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) IT (Prematurely Ended) BG (Prematurely Ended) PT (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2020-001028-32 Sponsor Protocol Number: CIVI/2018/NH-01 Start Date*: 2020-09-09
    Sponsor Name:CHU DE NIMES
    Full Title: Safety and Efficacy of Neoadjuvant immunotherapy with Durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (Gemcitabin/Cisplatin or Gemcitabin/Carboplatin) in patients with operable,...
    Medical condition: The patient has a histologically-confirmed (ureteroscopic biopsy) or cytologically(urine cytology)-confirmed diagnosis of high-grade urothelial carcinoma of the renal pelvis or ureter. Presence of ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000695-28 Sponsor Protocol Number: VitDURO-AECC17-01 Start Date*: 2018-07-04
    Sponsor Name:Hospital Universitari Germans Trias i Pujol
    Full Title: Pilot study of Vitamin D biological effects in patients with resectable urinary tract urothelial carcinoma.
    Medical condition: Patients with resectable urinary tract urothelial carcinoma candidates to radical cystectomy o nephroureterectomy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046718 Urothelial carcinoma bladder stage I, with cancer in situ LLT
    20.0 100000004864 10046720 Urothelial carcinoma bladder stage II LLT
    20.0 100000004864 10046721 Urothelial carcinoma bladder stage III LLT
    20.0 100000004864 10046724 Urothelial carcinoma ureter local LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004090-82 Sponsor Protocol Number: ON/2011/3775 Start Date*: 2012-02-06
    Sponsor Name:University Hospitals Bristol NHS Foundation Trust Research and Innovation Department
    Full Title: A Phase II Trial of Combination Cabazitaxel and Cisplatin Chemotherapy in the Neoadjuvant Treatment of Transitional Cell Carcinoma of the Urinary Bladder
    Medical condition: Muscle invasive transitional cell carcinoma of the urinary bladder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066753 Bladder transitional cell carcinoma stage II PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005084 Bladder transitional cell carcinoma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066754 Bladder transitional cell carcinoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-000205-24 Sponsor Protocol Number: G1T28-209 Start Date*: 2021-10-28
    Sponsor Name:G1 Therapeutics, Inc.
    Full Title: A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered with First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients with Untreated, Locally Advanced or Meta...
    Medical condition: Untreated, Locally Advanced or Metastatic Urothelial Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002646-16 Sponsor Protocol Number: 17000139BLC2001 Start Date*: 2021-04-26
    Sponsor Name:Janssen-Cilag International NV
    Full Title: Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants with High-Risk Non-Muscle Invasive Bladder Cance...
    Medical condition: Non-Muscle-Invasive Urothelial Carcinoma (NMIBC) of the Bladder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    21.0 100000004864 10046720 Urothelial carcinoma bladder stage II LLT
    21.0 100000004864 10046721 Urothelial carcinoma bladder stage III LLT
    21.0 100000004864 10046722 Urothelial carcinoma bladder stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) PT (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 23:16:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA